Endothelial Function and Progenitor Cells in Acute Ischemic Stroke
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Ischemic Stroke
- Sponsor
- Charite University, Berlin, Germany
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Levels of cEPC
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to determine whether levels of circulating endothelial progenitor cells (cEPC) are increased in the acute phase of ischemic stroke.
Detailed Description
Endothelial dysfunction is a key component of atherosclerosis which contributes to the development of cardio- and cerebrovascular diseases. However, endothelial dysfunction (ED) is not established as a risk factor for ischemic stroke. As a novelty the proposed trial investigates the following variety of indirect markers of endothelial function in acute ischemic stroke: circulating endothelial progenitor cells (EPC), endothelial microparticles (EMP), ENDOPAT (RH- PAT ratio) in two regards: 1. time after ischemic events (\< 48h, Days 4-5, day 7 or at discharge) 2. etiological stroke subtypes It is not known whether these parameters are changed after acute cerebral ischemia and could possibly serve as specific target for treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with first ever ischemic stroke
- •TIA, or transient symptoms with infarction (TSI)
- •Age \> or = 18 years old within 24 hours after onset
- •Written informed consent to participate
- •No evidence for dysphagia
Exclusion Criteria
- •Malignant hematopoietic disease (e.g. leukemia), severe systemic infections, severe immunological disease, renal or hepatic failure
- •Pancreatitis, cholecystolithiasis, intestinal malabsorption
- •Lactose intolerance
- •Increased risk of aspiration
- •Pregnancy
- •Life expectancy less than 12 months
- •Inability to give written informed consent
- •Psychosis
- •Alcohol dependency
- •Abuse of illegal drugs
Outcomes
Primary Outcomes
Levels of cEPC
Time Frame: <48h, day 4-5, discharge or day 7
Levels of cEPC (CD34+/CD133+/VEGF2R+/CD31) in % of mononuclear cells using flow cytometry with respect to stroke subtypes.
Secondary Outcomes
- Levels of EMP(<48h, day 4-5, day 7 or discharge)
- ENDOPAT(<48h, day 4-5,day 7)